Johnson & Johnson

Johnson & Johnson logo
🇺🇸United States
Ownership
Public
Established
1886-01-01
Employees
131.9K
Market Cap
$392.2B
Website
http://www.jnj.com
Introduction

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Clinical Trials
Related News
pharmaphorum.com
·

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

Johnson & Johnson plans phase 3 trials for Rybrevant in colorectal cancer after phase 1b/2 OrigAMI-1 study showed 49% ORR in RAS/BRAF wild-type mCRC patients, with 7.4 months median duration of response and 88% disease control rate. Rybrevant also achieved 53% ORR in liver-metastasized cases, with 21% eligible for curative surgery.
whatech.com
·

Global Statins Market Insights Discussed Regarding Key Insights and Leading Countries

The statins market, valued at $22B, is projected to reach $15B by 2021, driven by cardiovascular disease prevalence, cholesterol management awareness, and statin formulation advancements. Challenges include generic competition, alternative therapies, and side effects. Opportunities lie in combination therapies and emerging markets.
mychesco.com
·

FDA Approves TREMFYA® for Ulcerative Colitis Treatment, Promising New Hope for Patients

Johnson & Johnson's TREMFYA® (guselkumab) receives FDA approval for adults with moderately to severely active ulcerative colitis (UC), marking the first fully-human, dual-acting monoclonal antibody targeting both IL-23 and the CD64 receptor. The QUASAR study results show significant clinical and endoscopic remission rates, offering a new treatment option for UC.
biospace.com
·

RYBREVANT® (amivantamab) plus chemotherapy shows positive overall survival trend

Updated MARIPOSA-2 study results show amivantamab plus chemotherapy significantly improves post-progression outcomes and overall survival in previously treated NSCLC patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone.

Related Clinical Trials:

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
drugs.com
·

Neoadjuvant TAR-200 Plus Cetrelimab Nearly Doubles the Pathological Complete Response Rate Compared to Cetrelimab Alone in Patients with Muscle-Invasive Bladder Cancer

Neoadjuvant TAR-200 plus cetrelimab nearly doubles pathological complete response rate in muscle-invasive bladder cancer patients compared to cetrelimab alone, according to interim data from the SunRISe-4 study presented at ESMO 2024.

Related Clinical Trials:

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
mondaq.com
·

Life Sciences Licensing And M&A Update: Catching Up On Recent Decisions Affecting

Recent Delaware Chancery Court and Third Circuit decisions impact life sciences licensing and M&A transactions, with rulings on commercially reasonable efforts in acquisitions and post-patent expiration royalty obligations.
rttnews.com
·

J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk ...

Johnson & Johnson announced Phase 2b SunRISe-1 study results showing TAR-200's 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9 months.
janssen.com
·

RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response

RYBREVANT® (amivantamab-vmjw) combined with chemotherapy showed promising antitumor activity in RAS/BRAF wild-type metastatic colorectal cancer patients not previously treated with EGFR therapy, with a median duration of response of 7.4 months. 21% of patients underwent curative-intent surgery, and the safety profile was manageable without new safety signals.

Related Clinical Trials:

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
globenewswire.com
·

New data from TAR-200 Phase 2b SunRISe-1 study show 84

TAR-200 monotherapy shows 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9.2 months, highlighting its potential as a bladder-sparing treatment alternative to radical cystectomy.

Related Clinical Trials:

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
prnewswire.com
·

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response

TAR-200 monotherapy shows 83.5% complete response rate in BCG-unresponsive HR-NMIBC patients, with 82% maintaining response after 9 months.

Related Clinical Trials:

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy